Cytodyn Inc (CYDY)

[Saltz]

In reference to the S2C results think about what we know from the 60 EIND patients. Many were riddled w pre existing conditions and Leronlimab still saved many of those predisposed patients lives. This trial does not allow the very sick patients to participate. Nader has said there are a high number of deaths in the S2C trial.

Do you not think Leronlimab is going to show superior efficacy compared to the placebo arm? It would not surprise me if Leronlimab arm has zero to very few deaths.

With a 2:1 ratio of drug vs placebo let’s take a guess at the current 150 patients enrolled.

50 placebo - 10 deaths

100 Leronlimab - 2 deaths

That would equate to 1 death for every 10 deaths in the placebo arm.

Is that enough statistical relevance to halt the placebo arm or possibly halt the trial and grant emergency approval?

I personally don’t think those numbers are far reaching when one considers Leronlimab’s efficacy for severe patients up to this point. Just rewatch the Patterson Ted Talk and think it through again.

A17, I know you play the devils advocate w everything. Throw the devil at the S2C trial - he’s going to find a different place to play. As Lalezari has stated many times this is a home run.